{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:17:56Z","timestamp":1791839876015,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,29]]},"DOI":"10.7759\/cureus.41125","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T07:46:07Z","timestamp":1688024767000},"source":"Crossref","is-referenced-by-count":7,"title":["The Effectiveness of Anti-Interleukin-17A Treatment for Pityriasis Rubra Pilaris: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Mohammad","family":"Abduljawad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamer H","family":"Alsharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin G","family":"Gronfula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talah K","family":"Magadmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujain I","family":"Khayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M","family":"Fageeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulqader A","family":"Almuallim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ayman","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Albadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2016.09.006","article-title":"Successful treatment of type II pityriasis rubra pilaris with secukinumab","volume":"2","author":"Gauci ML","year":"2016","unstructured":"Gauci ML, Jachiet M, Gottlieb J, Madeleine-Chambrin I, Rybojad M, Bagot M, Bouaziz JD. Successful treatment of type II pityriasis rubra pilaris with secukinumab. JAAD Case Rep. 2016, 2:462-4. 10.1016\/j.jdcr.2016.09.006","journal-title":"JAAD Case Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0338-1","article-title":"A review on pityriasis rubra pilaris","volume":"19","author":"Wang D","year":"2018","unstructured":"Wang D, Chong VC, Chong WS, Oon HH. A review on pityriasis rubra pilaris. Am J Clin Dermatol. 2018, 19:377-90. 10.1007\/s40257-017-0338-1","journal-title":"Am J Clin Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(94)70271-3","article-title":"Treatment of classic pityriasis rubra pilaris","volume":"31","author":"Dicken CH","year":"1994","unstructured":"Dicken CH. Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol. 1994, 31:997-9. 10.1016\/s0190-9622(94)70271-3","journal-title":"J Am Acad Dermatol"},{"key":"ref4","article-title":"Pityriasis rubra pilaris sensitive to narrow band-ultraviolet B light therapy","volume":"8","author":"Vergilis-Kalner IJ","year":"2009","unstructured":"Vergilis-Kalner IJ, Mann DJ, Wasserman J, Petronic-Rosic V, Tsoukas MM. Pityriasis rubra pilaris sensitive to narrow band-ultraviolet B light therapy. J Drugs Dermatol. 2009, 8:270-3.","journal-title":"J Drugs Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.3885","article-title":"Successful treatment of refractory pityriasis rubra pilaris with secukinumab","volume":"152","author":"Schuster D","year":"2016","unstructured":"Schuster D, Pfister-Wartha A, Bruckner-Tuderman L, Schempp CM. Successful treatment of refractory pityriasis rubra pilaris with secukinumab. JAMA Dermatol. 2016, 152:1278-80. 10.1001\/jamadermatol.2016.3885","journal-title":"JAMA Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021, 88:105906. 10.1016\/j.ijsu.2021.105906","journal-title":"Int J Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.06.009","article-title":"Pityriasis rubra pilaris response to IL-17A inhibition is associated with IL-17C and CCL20 protein levels","volume":"142","author":"Strunck JL","year":"2022","unstructured":"Strunck JL, Cutler B, Rajpal B, et al.. Pityriasis rubra pilaris response to IL-17A inhibition is associated with IL-17C and CCL20 protein levels. J Invest Dermatol. 2022, 142:235-239.e1. 10.1016\/j.jid.2021.06.009","journal-title":"J Invest Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13644","article-title":"Successful treatment of resistant pityriasis rubra pilaris with ixekizumab","volume":"33","author":"Penalba-Torres M","year":"2020","unstructured":"Penalba-Torres M, Pinilla-Mart\u00edn B, Arag\u00f3n-Miguel R, Velasco-Tamariz V, Rivera-D\u00edaz R. Successful treatment of resistant pityriasis rubra pilaris with ixekizumab. Dermatol Ther. 2020, 33:e13644. 10.1111\/dth.13644","journal-title":"Dermatol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_1079_21","article-title":"Juvenile pityriasis rubra pilaris in a 4-year-old child treated successfully with secukinumab","volume":"67","author":"Albela H","year":"2022","unstructured":"Albela H, Lee WQ, Nordin SN, Gopinathan LP, A Ramli MN, Leong KF. Juvenile pityriasis rubra pilaris in a 4-year-old child treated successfully with secukinumab. Indian J Dermatol. 2022, 67:601-3. 10.4103\/ijd.ijd_1079_21","journal-title":"Indian J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2019.3502","article-title":"Successful treatment of TNF\u03b1 inhibitor-resistant pityriasis rubra pilaris with ixekizumab and acitretin","volume":"29","author":"Chastagner M","year":"2019","unstructured":"Chastagner M, Hoelt P, Kanitakis J, Jullien D, Villani AP. Successful treatment of TNF\u03b1 inhibitor-resistant pityriasis rubra pilaris with ixekizumab and acitretin. Eur J Dermatol. 2019, 29:218-20. 10.1684\/ejd.2019.3502","journal-title":"Eur J Dermatol"},{"key":"ref11","article-title":"Response of persistent juvenile pityriasis rubra pilaris to secukinumab","volume":"74","author":"Kevric I","year":"2016","unstructured":"Kevric I, Sluzevich J. Response of persistent juvenile pityriasis rubra pilaris to secukinumab. JAAD Case Rep. 2016, 74:AB268.","journal-title":"JAAD Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0932","article-title":"Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: a single-arm trial","volume":"156","author":"Haynes D","year":"2020","unstructured":"Haynes D, Strunck JL, Topham CA, et al.. Evaluation of ixekizumab treatment for patients with pityriasis rubra pilaris: a single-arm trial. JAMA Dermatol. 2020, 156:668-75. 10.1001\/jamadermatol.2020.0932","journal-title":"JAMA Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.02.007","article-title":"Secukinumab in pityriasis rubra pilaris: a case series demonstrating variable response and the need for minimal clinical datasets","volume":"4","author":"Wain T","year":"2018","unstructured":"Wain T, Choy B, Satchell AC, Woods JA, Frew JW. Secukinumab in pityriasis rubra pilaris: a case series demonstrating variable response and the need for minimal clinical datasets. JAAD Case Rep. 2018, 4:500-5. 10.1016\/j.jdcr.2018.02.007","journal-title":"JAAD Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15353","article-title":"Successful treatment of severe pityriasis rubra pilaris with secukinumab in a 3-year-old boy","volume":"47","author":"Xu YH","year":"2022","unstructured":"Xu YH, Dong DD, Lin YF, Wang Q, Huang LM, Shi JQ. Successful treatment of severe pityriasis rubra pilaris with secukinumab in a 3-year-old boy. Clin Exp Dermatol. 2022, 47:2043-5. 10.1111\/ced.15353","journal-title":"Clin Exp Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21708","article-title":"Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis","volume":"187","author":"Boudreaux BW","year":"2022","unstructured":"Boudreaux BW, Pincelli TP, Bhullar PK, et al.. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis. Br J Dermatol. 2022, 187:650-8. 10.1111\/bjd.21708","journal-title":"Br J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.23736\/S2784-8671.20.06743-7","article-title":"Secukinumab is an effective and safe treatment for refractory pityriasis rubra pilaris","volume":"156","author":"Papini M","year":"2021","unstructured":"Papini M, Russo A, Natalini Y, Troiani L, Cassiani L. Secukinumab is an effective and safe treatment for refractory pityriasis rubra pilaris. Ital J Dermatol Venerol. 2021, 156:501-2. 10.23736\/S2784-8671.20.06743-7","journal-title":"Ital J Dermatol Venerol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14114","article-title":"Ustekinumab treatment of pityriasis rubra pilaris: a report of five cases","volume":"45","author":"Napolitano M","year":"2018","unstructured":"Napolitano M, Lembo L, Fania L, Abeni D, Didona D, Didona B. Ustekinumab treatment of pityriasis rubra pilaris: a report of five cases. J Dermatol. 2018, 45:202-6. 10.1111\/1346-8138.14114","journal-title":"J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14709","article-title":"Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12\/23 p40","volume":"46","author":"Matsuda T","year":"2019","unstructured":"Matsuda T, Yamazaki F, Ueda-Hayakawa I, Kambe N, Okamoto H. Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12\/23 p40. J Dermatol. 2019, 46:70-2. 10.1111\/1346-8138.14709","journal-title":"J Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.139","article-title":"Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination","volume":"3","author":"Liu YT","year":"2022","unstructured":"Liu YT, Wang SS. Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination. Skin Health Dis. 2022, 3:e139. 10.1002\/ski2.139","journal-title":"Skin Health Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14097","article-title":"Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: a case report and literature review","volume":"33","author":"Liang JY","year":"2020","unstructured":"Liang JY, Ye RX, Tian X, Zhang SQ, Zhang XB. Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: a case report and literature review. Dermatol Ther. 2020, 33:e14097. 10.1111\/dth.14097","journal-title":"Dermatol Ther"},{"key":"ref21","article-title":"Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris","volume":"101","author":"Bonomo L","year":"2018","unstructured":"Bonomo L, Levitt JO. Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris. Cutis. 2018, 101:367-9.","journal-title":"Cutis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.05.006","article-title":"Successful treatment of type I pityriasis rubra pilaris with ixekizumab","volume":"4","author":"Heibel MD","year":"2018","unstructured":"Heibel MD, Heibel HD. Successful treatment of type I pityriasis rubra pilaris with ixekizumab. JAAD Case Rep. 2018, 4:774-6. 10.1016\/j.jdcr.2018.05.006","journal-title":"JAAD Case Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000488902","article-title":"Successful treatment of pityriasis rubra pilaris with ixekizumab","volume":"10","author":"Hanfstingl K","year":"2018","unstructured":"Hanfstingl K, Pekar-Lukacs A, Motz R, Guenova E, Hoetzenecker W. Successful treatment of pityriasis rubra pilaris with ixekizumab. Case Rep Dermatol. 2018, 10:97-100. 10.1159\/000488902","journal-title":"Case Rep Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.0091","article-title":"Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: a case series of 100 patients","volume":"152","author":"Ross NA","year":"2016","unstructured":"Ross NA, Chung HJ, Li Q, Andrews JP, Keller MS, Uitto J. Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: a case series of 100 patients. JAMA Dermatol. 2016, 152:670-5. 10.1001\/jamadermatol.2016.0091","journal-title":"JAMA Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70158-x","article-title":"Acitretin in the treatment of severe disorders of keratinization. Results of an open study","volume":"24","author":"Blanchet-Bardon C","year":"1991","unstructured":"Blanchet-Bardon C, Nazzaro V, Rognin C, Geiger JM, Puissant A. Acitretin in the treatment of severe disorders of keratinization. Results of an open study. J Am Acad Dermatol. 1991, 24:982-6. 10.1016\/0190-9622(91)70158-x","journal-title":"J Am Acad Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13550","article-title":"Refractory pityriasis rubra pilaris with good response after treatment with ustekinumab","volume":"16","author":"Arag\u00f3n-Miguel R","year":"2018","unstructured":"Arag\u00f3n-Miguel R, Prieto-Barrios M, Calleja-Algarra A, Velasco-Tamariz V, Andres-Lencina JJ, Ortiz-Romero P, Mons\u00e1lvez-Honrubia V. Refractory pityriasis rubra pilaris with good response after treatment with ustekinumab. J Dtsch Dermatol Ges. 2018, 16:1022-5. 10.1111\/ddg.13550","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(90)70110-4","article-title":"Pityriasis rubra pilaris: further observations of systemic retinoid therapy","volume":"22","author":"Borok M","year":"1990","unstructured":"Borok M, Lowe NJ. Pityriasis rubra pilaris: further observations of systemic retinoid therapy. J Am Acad Dermatol. 1990, 22:792-5. 10.1016\/0190-9622(90)70110-4","journal-title":"J Am Acad Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad MH","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018, 23:60-3. 10.1136\/bmjebm-2017-110853","journal-title":"BMJ Evid Based Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1159\/000337546","article-title":"Pityriasis rubra pilaris: treatment with biologics - a new promising therapy?","volume":"224","author":"Ivanova K","year":"2012","unstructured":"Ivanova K, Itin P, Haeusermann P. Pityriasis rubra pilaris: treatment with biologics - a new promising therapy?. Dermatology. 2012, 224:120-5. 10.1159\/000337546","journal-title":"Dermatology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14761","article-title":"Pityriasis rubra pilaris: algorithms for diagnosis and treatment","volume":"32","author":"Roenneberg S","year":"2018","unstructured":"Roenneberg S, Biedermann T. Pityriasis rubra pilaris: algorithms for diagnosis and treatment. J Eur Acad Dermatol Venereol. 2018, 32:889-98. 10.1111\/jdv.14761","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/165933-the-effectiveness-of-anti-interleukin-17a-treatment-for-pityriasis-rubra-pilaris-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:41Z","timestamp":1707509141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/165933-the-effectiveness-of-anti-interleukin-17a-treatment-for-pityriasis-rubra-pilaris-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.41125","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,29]]}}}